clinical trial · NCT03882255
A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State
Janssen Pharmaceutica N.V., Belgium·phase1·completed·n = 52
HealthyPonesimod dose range (2 - 20 mg)Placebo PropranololPropranolol 80 mg
brief summary
The primary purpose of this study is to evaluate the effect of the up-titration regimen of ponesimod on heart rate (HR) and other electrocardiogram (ECG) parameters when administrated to healthy adult participants receiving propranolol at steady state.
started
Mar 20, 2019
primary completion
Aug 26, 2019
completion
Aug 26, 2019
last updated
Apr 27, 2025
official title
A Randomized, Double-blind, Parallel-group, 2-period, Placebo-controlled, Phase 1 Study to Investigate the Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of the Up-titration Regimen of Ponesimod in Healthy Adult Subjects Receiving Propranolol at Steady State
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol